APTO
Aptose Biosciences Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website aptose.com
- Employees(FY) 35
- ISIN CA03835T3091
Performance
-4.07%
1W
-7.09%
1M
-39.55%
3M
-57.4%
6M
-53.54%
YTD
-83.53%
1Y
Profile
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Technical Analysis of APTO 2024-05-10
Overview:
In analyzing the technical indicators for APTO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been consistently above the S...
Recent News & Updates
- 2023-06-10 00:00
Aptose Presents Highlights from Clinical Update(Yahoo Finance)
- 2023-06-04 19:30
Aptose Biosciences Provides Update on Reverse Stock Split(Yahoo Finance)
- 2023-05-30 19:30
- 2023-05-25 04:14
Aptose Enters into $25 Million Committed Equity Facility(Yahoo Finance)
- 2023-05-23 05:30
- 2023-05-20 22:03
3 Stocks With 1,000% Upside Potential(Yahoo Finance)
- 2023-05-10 19:28
Aptose Biosciences Inc.'s (TSE:APS) Path To Profitability(Yahoo Finance)
- 2023-05-08 04:13
Aptose Biosciences: Q1 Earnings Snapshot(Yahoo Finance)
- 2023-05-08 04:01
Aptose Reports Results for the First Quarter 2023(Yahoo Finance)
- 2023-05-03 19:01
- 2023-04-23 19:01
- 2023-04-10 04:01
- 2023-03-28 04:01
- 2023-03-27 21:40
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?(Yahoo Finance)
- 2023-03-26 20:45
- 2023-03-23 04:44
- 2023-03-10 05:44
- 2023-03-09 03:05
- 2023-03-01 18:30
- 2023-01-29 18:00
- 2022-12-29 19:02
- 2022-12-27 18:30
- 2022-12-11 17:15
Aptose Biosciences Establishes New At-The-Market Facility(Yahoo Finance)
- 2022-12-10 20:00
- 2022-12-07 03:05
- 2022-11-13 18:30
- 2022-11-02 21:10
- 2022-11-01 04:01
Aptose Reports Results for the Third Quarter 2022(Yahoo Finance)
- 2022-10-18 04:01
- 2022-09-29 20:59
Horizon (HZNP) Completes Enrollment in Phase IV TED Study(Yahoo Finance)